Header Logo

Connection

LEO LUZNIK to Transplantation Conditioning

Back to Details
This is a "connection" page, showing publications LEO LUZNIK has written about Transplantation Conditioning.
LEO LUZNIK
Connection Strength
7.351
Transplantation Conditioning
  1. Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor-Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies. J Clin Oncol. 2022 02 01; 40(4):356-368.
    View in: PubMed
    Score: 0.674
  2. Post-transplantation cyclophosphamide for chimerism-based tolerance. Bone Marrow Transplant. 2019 08; 54(Suppl 2):769-774.
    View in: PubMed
    Score: 0.573
  3. Immune reconstitution after T-cell replete HLA-haploidentical transplantation. Semin Hematol. 2019 07; 56(3):221-226.
    View in: PubMed
    Score: 0.559
  4. Development of Grade II Acute Graft-versus-Host Disease Is Associated with Improved Survival after Myeloablative HLA-Matched Bone Marrow Transplantation using Single-Agent Post-Transplant Cyclophosphamide. Biol Blood Marrow Transplant. 2019 06; 25(6):1128-1135.
    View in: PubMed
    Score: 0.550
  5. Induction of Major Histocompatibility Complex-mismatched Mouse Lung Allograft Acceptance With Combined Donor Bone Marrow: Lung Transplant Using a 12-Hour Nonmyeloablative Conditioning Regimen. Transplantation. 2016 Dec; 100(12):e140-e146.
    View in: PubMed
    Score: 0.476
  6. Might haplo "be the (better) match"? Blood. 2016 Feb 18; 127(7):799-800.
    View in: PubMed
    Score: 0.451
  7. Therapeutic drug monitoring for either oral or intravenous busulfan when combined with pre- and post-transplantation cyclophosphamide. Leuk Lymphoma. 2016; 57(3):666-75.
    View in: PubMed
    Score: 0.440
  8. Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning. J Clin Oncol. 2014 Nov 01; 32(31):3497-505.
    View in: PubMed
    Score: 0.410
  9. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008 Jun; 14(6):641-50.
    View in: PubMed
    Score: 0.264
  10. How I prevent GVHD in high-risk patients: posttransplant cyclophosphamide and beyond. Blood. 2023 01 05; 141(1):49-59.
    View in: PubMed
    Score: 0.182
  11. Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide. Blood. 2001 Dec 01; 98(12):3456-64.
    View in: PubMed
    Score: 0.168
  12. National Marrow Donor Program-Sponsored Multicenter, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation Using Post-Transplant Cyclophosphamide. J Clin Oncol. 2021 06 20; 39(18):1971-1982.
    View in: PubMed
    Score: 0.162
  13. PTCy and "The Story of the Three Bears". Bone Marrow Transplant. 2021 04; 56(4):765-766.
    View in: PubMed
    Score: 0.157
  14. Shortened-Duration Immunosuppressive Therapy after Nonmyeloablative, Related HLA-Haploidentical or Unrelated Peripheral Blood Grafts and Post-Transplantation Cyclophosphamide. Biol Blood Marrow Transplant. 2020 11; 26(11):2075-2081.
    View in: PubMed
    Score: 0.154
  15. Severe Cytokine Release Syndrome after Haploidentical Peripheral Blood Stem Cell Transplantation. Biol Blood Marrow Transplant. 2019 12; 25(12):2431-2437.
    View in: PubMed
    Score: 0.143
  16. Allogeneic Blood or Marrow Transplantation with Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Multiple Myeloma. Biol Blood Marrow Transplant. 2017 Nov; 23(11):1903-1909.
    View in: PubMed
    Score: 0.124
  17. Plasma-derived proteomic biomarkers in human leukocyte antigen-haploidentical or human leukocyte antigen-matched bone marrow transplantation using post-transplantation cyclophosphamide. Haematologica. 2017 05; 102(5):932-940.
    View in: PubMed
    Score: 0.120
  18. Nonmyeloablative Haploidentical Bone Marrow Transplantation with Post-Transplantation Cyclophosphamide for Pediatric and Young Adult Patients with High-Risk Hematologic Malignancies. Biol Blood Marrow Transplant. 2017 Feb; 23(2):325-332.
    View in: PubMed
    Score: 0.119
  19. Anti-CD45 radioimmunotherapy without TBI before transplantation facilitates persistent haploidentical donor engraftment. Blood. 2016 Jan 21; 127(3):352-9.
    View in: PubMed
    Score: 0.111
  20. Outcomes of Nonmyeloablative HLA-Haploidentical Blood or Marrow Transplantation With High-Dose Post-Transplantation Cyclophosphamide in Older Adults. J Clin Oncol. 2015 Oct 01; 33(28):3152-61.
    View in: PubMed
    Score: 0.109
  21. Phase II Study of Nonmyeloablative Allogeneic Bone Marrow Transplantation for B Cell Lymphoma with Post-Transplantation Rituximab and Donor Selection Based First on Non-HLA Factors. Biol Blood Marrow Transplant. 2015 Dec; 21(12):2115-2122.
    View in: PubMed
    Score: 0.108
  22. Experts' considerations on HLA-haploidentical stem cell transplantation. Eur J Haematol. 2014 Sep; 93(3):187-97.
    View in: PubMed
    Score: 0.099
  23. Outcomes of related donor HLA-identical or HLA-haploidentical allogeneic blood or marrow transplantation for peripheral T cell lymphoma. Biol Blood Marrow Transplant. 2013 Apr; 19(4):602-6.
    View in: PubMed
    Score: 0.091
  24. Post-transplantation cyclophosphamide for tolerance induction in HLA-haploidentical bone marrow transplantation. Semin Oncol. 2012 Dec; 39(6):683-93.
    View in: PubMed
    Score: 0.090
  25. 5-azacytidine as salvage treatment in relapsed myeloid tumors after allogeneic bone marrow transplantation. Biol Blood Marrow Transplant. 2011 May; 17(5):754-8.
    View in: PubMed
    Score: 0.078
  26. High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. Blood. 2010 Apr 22; 115(16):3224-30.
    View in: PubMed
    Score: 0.074
  27. Successful pregnancy and childbirth after reduced-intensity conditioning and partially HLA-mismatched BMT. Bone Marrow Transplant. 2009 Jun; 43(12):969-70.
    View in: PubMed
    Score: 0.069
  28. Salvage transplantation for allograft failure using fludarabine and alemtuzumab as conditioning regimen. Bone Marrow Transplant. 2009 Mar; 43(6):477-80.
    View in: PubMed
    Score: 0.068
  29. Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma. Biol Blood Marrow Transplant. 2008 Nov; 14(11):1279-87.
    View in: PubMed
    Score: 0.068
  30. Rapamycin promotes emergence of IL-10-secreting donor lymphocyte infusion-derived T cells without compromising their graft-versus-leukemia reactivity. Transplantation. 2007 Mar 15; 83(5):631-40.
    View in: PubMed
    Score: 0.061
  31. Mismatched donor transplantation with post-transplantation cyclophosphamide for advanced cutaneous T-cell lymphoma: a single-center retrospective study. Leuk Lymphoma. 2022 12; 63(12):2987-2991.
    View in: PubMed
    Score: 0.044
  32. Posttransplantation cyclophosphamide facilitates engraftment of major histocompatibility complex-identical allogeneic marrow in mice conditioned with low-dose total body irradiation. Biol Blood Marrow Transplant. 2002; 8(3):131-8.
    View in: PubMed
    Score: 0.042
  33. Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2002; 8(7):377-86.
    View in: PubMed
    Score: 0.042
  34. Allogeneic transplantation for Ph+ acute lymphoblastic leukemia with posttransplantation cyclophosphamide. Blood Adv. 2020 10 27; 4(20):5078-5088.
    View in: PubMed
    Score: 0.039
  35. Thrombotic Microangiopathy after Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis. Biol Blood Marrow Transplant. 2020 12; 26(12):2306-2310.
    View in: PubMed
    Score: 0.039
  36. Allogeneic bone marrow transplantation with post-transplant cyclophosphamide for patients with HIV and haematological malignancies: a feasibility study. Lancet HIV. 2020 09; 7(9):e602-e610.
    View in: PubMed
    Score: 0.038
  37. Non-Myeloablative Allogeneic Transplantation with Post-Transplant Cyclophosphamide after Immune Checkpoint Inhibition for Classic Hodgkin Lymphoma: A Retrospective Cohort Study. Biol Blood Marrow Transplant. 2020 09; 26(9):1679-1688.
    View in: PubMed
    Score: 0.038
  38. Haploidentical BMT for severe aplastic anemia with intensive GVHD prophylaxis including posttransplant cyclophosphamide. Blood Adv. 2020 04 28; 4(8):1770-1779.
    View in: PubMed
    Score: 0.038
  39. Haploidentical transplantation using posttransplant cyclophosphamide as GVHD prophylaxis in patients over age 70. Blood Adv. 2019 09 10; 3(17):2608-2616.
    View in: PubMed
    Score: 0.036
  40. The European Society for Blood and Marrow Transplantation (EBMT) consensus recommendations for donor selection in haploidentical hematopoietic cell transplantation. Bone Marrow Transplant. 2020 01; 55(1):12-24.
    View in: PubMed
    Score: 0.035
  41. Early Fever after Haploidentical Bone Marrow Transplantation Correlates with Class II HLA-Mismatching and Myeloablation but Not Outcomes. Biol Blood Marrow Transplant. 2018 10; 24(10):2056-2064.
    View in: PubMed
    Score: 0.033
  42. Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia. Blood. 2015 Aug 20; 126(8):1033-40.
    View in: PubMed
    Score: 0.027
  43. Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide. Blood. 2015 May 07; 125(19):3024-31.
    View in: PubMed
    Score: 0.026
  44. HLA-haploidentical donor lymphocyte infusions for patients with relapsed hematologic malignancies after related HLA-haploidentical bone marrow transplantation. Biol Blood Marrow Transplant. 2014 Mar; 20(3):314-8.
    View in: PubMed
    Score: 0.024
  45. HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease. Blood. 2012 Nov 22; 120(22):4285-91.
    View in: PubMed
    Score: 0.022
  46. Human leukocyte antigen-haploidentical hematopoietic stem cell transplant for a patient with histiocytic sarcoma. Leuk Lymphoma. 2013 Mar; 54(3):655-7.
    View in: PubMed
    Score: 0.022
  47. Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome. Biol Blood Marrow Transplant. 2010 Apr; 16(4):482-9.
    View in: PubMed
    Score: 0.018
  48. Myeloablative allogeneic bone marrow transplant using T cell depleted allografts followed by post-transplant GM-CSF in high-risk myelodysplastic syndromes. Leuk Res. 2008 Sep; 32(9):1439-47.
    View in: PubMed
    Score: 0.016
  49. Induction of autologous graft-versus-host disease: results of a randomized prospective clinical trial in patients with poor risk lymphoma. Biol Blood Marrow Transplant. 2007 Oct; 13(10):1185-91.
    View in: PubMed
    Score: 0.016
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.